Ibrutinib and Venetoclax for First-Line Treatment of CLL von Jain, Nitin, Keating, Michael, Thompson, Philip, Ferrajoli, Alessandra, Burger, Jan, Borthakur, Gautam, Takahashi, Koichi, Estrov, Zeev, Fowler, Nathan, Kadia, Tapan, Konopleva, Marina, Alvarado, Yesid, Yilmaz, Musa, DiNardo, Courtney, Bose, Prithviraj, Ohanian, Maro, Pemmaraju, Naveen, Jabbour, Elias, Sasaki, Koji, Kanagal-Shamanna, Rashmi, Patel, Keyur, Jorgensen, Jeffrey, Garg, Naveen, Wang, Xuemei, Sondermann, Katrina, Cruz, Nichole, Wei, Chongjuan, Ayala, Ana, Plunkett, William, Kantarjian, Hagop, Gandhi, Varsha, Wierda, William

Volltext

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia von Naqvi, Kiran, Jabbour, Elias, Skinner, Jeffrey, Anderson, Kristin, Dellasala, Sara, Yilmaz, Musa, Ferrajoli, Alessandra, Bose, Prithviraj, Thompson, Philip, Alvarado, Yesid, Jain, Nitin, Takahashi, Koichi, Burger, Jan, Estrov, Zeev, Borthakur, Gautam, Pemmaraju, Naveen, Paul, Shilpa, Cortes, Jorge, Kantarjian, Hagop M.

Volltext

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis von Verstovsek, Srdan, Kantarjian, Hagop, Mesa, Ruben A, Pardanani, Animesh D, Cortes-Franco, Jorge, Thomas, Deborah A, Estrov, Zeev, Fridman, Jordan S, Bradley, Edward C, Erickson-Viitanen, Susan, Vaddi, Kris, Levy, Richard, Tefferi, Ayalew

Volltext

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes von Kadia, Tapan M., Jain, Preetesh, Ravandi, Farhad, Garcia‐Manero, Guillermo, Andreef, Michael, Takahashi, Koichi, Borthakur, Gautam, Jabbour, Elias, Konopleva, Marina, Daver, Naval G., Dinardo, Courtney, Pierce, Sherry, Kanagal‐Shamanna, Rashmi, Patel, Keyur, Estrov, Zeev, Cortes, Jorge, Kantarjian, Hagop M.

Volltext

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN von Jabbour, Elias, Short, Nicholas J., Montalban-Bravo, Guillermo, Huang, Xuelin, Bueso-Ramos, Carlos, Qiao, Wei, Yang, Hui, Zhao, Chong, Kadia, Tapan, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Estrov, Zeev, Cortes, Jorge, Ravandi, Farhad, Alvarado, Yesid, Komrokji, Rami, Sekeres, Mikkael A., Steensma, David P., DeZern, Amy, Roboz, Gail, Kantarjian, Hagop, Garcia-Manero, Guillermo

Volltext

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia von Yin, Qingsong, Sivina, Mariela, Robins, Harlan, Yusko, Erik, Vignali, Marissa, O'Brien, Susan, Keating, Michael J, Ferrajoli, Alessandra, Estrov, Zeev, Jain, Nitin, Wierda, William G, Burger, Jan A

Volltext

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study von Jabbour, Elias, Dr, Kantarjian, Hagop, Prof, Ravandi, Farhad, Prof, Thomas, Deborah, Prof, Huang, Xuelin, Prof, Faderl, Stefan, Prof, Pemmaraju, Naveen, Prof, Daver, Naval, MD, Garcia-Manero, Guillermo, Prof, Sasaki, Koji, MD, Cortes, Jorge, Prof, Garris, Rebecca, Yin, C Cameron, MD, Khoury, Joseph D, MD, Jorgensen, Jeffrey, Prof, Estrov, Zeev, Prof, Bohannan, Zachary, MA, Konopleva, Marina, MD, Kadia, Tapan, MD, Jain, Nitin, MD, DiNardo, Courtney, MD, Wierda, William, Prof, Jeanis, Vicky, RN, O'Brien, Susan, Prof

Volltext

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes von Manshouri, Taghi, Veletic, Ivo, Li, Ping, Yin, C. Cameron, Post, Sean M., Verstovsek, Srdan, Estrov, Zeev

Volltext

Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy von Koppikar, Priya, Bhagwat, Neha, Kilpivaara, Outi, Manshouri, Taghi, Adli, Mazhar, Hricik, Todd, Liu, Fan, Saunders, Lindsay M., Mullally, Ann, Abdel-Wahab, Omar, Leung, Laura, Weinstein, Abby, Marubayashi, Sachie, Goel, Aviva, Gönen, Mithat, Estrov, Zeev, Ebert, Benjamin L., Chiosis, Gabriela, Nimer, Stephen D., Bernstein, Bradley E., Verstovsek, Srdan, Levine, Ross L.

Volltext

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera von QUINTAS-CARDAMA, Alfonso, KANTARJIAN, Hagop, VERSTOVSEK, Srdan, MANSHOURI, Taghi, LUTHRA, Rajyalakshmi, ESTROV, Zeev, PIERCE, Sherry, RICHIE, Mary Ann, BORTHAKUR, Gautam, KONOPLEVA, Marina, CORTES, Jorge

Volltext

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells von Sun, Michael, Estrov, Zeev, Ji, Yuan, Coombes, Kevin R, Harris, David H, Kurzrock, Razelle

Volltext

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis von Verstovsek, Srdan, Manshouri, Taghi, Pilling, Darrell, Bueso-Ramos, Carlos E, Newberry, Kate J, Prijic, Sanja, Knez, Liza, Bozinovic, Ksenija, Harris, David M, Spaeth, Erika L, Post, Sean M, Multani, Asha S, Rampal, Raajit K, Ahn, Jihae, Levine, Ross L, Creighton, Chad J, Kantarjian, Hagop M, Estrov, Zeev

Volltext

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy von Thompson, Philip A., Srivastava, Jaya, Peterson, Christine, Strati, Paolo, Jorgensen, Jeffrey L., Hether, Tyler, Keating, Michael J., O'Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Wierda, William G.

Volltext

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL von Strati, Paolo, Keating, Michael J., O’Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.

Volltext

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia von Naqvi, Kiran, Jabbour, Elias, Skinner, Jeffrey, Yilmaz, Musa, Ferrajoli, Alessandra, Bose, Prithviraj, Thompson, Philip, Alvarado, Yesid, Jain, Nitin, Takahashi, Koichi, Burger, Jan, Estrov, Zeev, Borthakur, Gautam, Pemmaraju, Naveen, Paul, Shilpa, Cortes, Jorge, Kantarjian, Hagop M.

Volltext

Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin von RAVANDI, Farhad, ESTEY, Eli, FERRAJOLI, Alessandra, VERSTOVSEK, Srdan, GARCIA-MANERO, Guillermo, CORTES, Jorge, KANTARJIAN, Hagop, JONES, Dan, FADED, Stefan, O'BRIEN, Susan, FIORENTINO, Jackie, PIERCE, Sherry, BLAMBLE, Deborah, ESTROV, Zeev, WIERDA, William

Volltext

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia von Bose, Prithviraj, Verstovsek, Srdan, Cortes, Jorge E., Tse, Susan, Gasior, Yvonne, Jain, Nitin, Jabbour, Elias J., Estrov, Zeev, Alvarado, Yesid, DiNardo, Courtney D., Pemmaraju, Naveen, Kornblau, Steven M., Kadia, Tapan M., Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Masarova, Lucia, Villareal, John, Pierce, Sherry A., Nogueras-Gonzalez, Graciela, Huang, Xuelin, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Ravandi, Farhad

Volltext

CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia von Sivina, Mariela, Xiao, Lianchun, Kim, Ekaterina, Vaca, Alicia, Chen, Shih-Shih, Keating, Michael J., Ferrajoli, Alessandra, Estrov, Zeev, Jain, Nitin, Wierda, William G., Huang, Xuelin, Chiorazzi, Nicholas, Burger, Jan A.

Volltext

Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations von Jain, Nitin, Thompson, Philip, Burger, Jan, Ferrajoli, Alessandra, Takahashi, Koichi, Estrov, Zeev, Borthakur, Gautam, Bose, Prithviraj, Kadia, Tapan, Pemmaraju, Naveen, Sasaki, Koji, Konopleva, Marina, Jabbour, Elias, Garg, Naveen, Wang, Xuemei, Kanagal-Shamanna, Rashmi, Patel, Keyur, Wang, Wei, Jorgensen, Jeffrey, Wang, Sa, Lopez, Wanda, Ayala, Ana, Plunkett, William, Gandhi, Varsha, Kantarjian, Hagop, O’Brien, Susan, Keating, Michael, Wierda, William G.

Volltext

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia von RAVANDI, Farhad, CORTES, Jorge E, PIERCE, Sherry R, BRANDT, Mark, BYRD, Anna, NEBIYOU BEKELE, B, PRATZ, Keith, LUTHRA, Rajyalakshmi, LEVIS, Mark, ANDREEFF, Michael, KANTARJIAN, Hagop M, JONES, Daniel, FADERL, Stefan, GARCIA-MANERO, Guillermo, KONOPLEVA, Marina Y, O'BRIEN, Susan, ESTROV, Zeev, BORTHAKUR, Gautam, THOMAS, Deborah

Volltext